-- Fosun Pharma Raises $512 Million in Offering at Bottom of Range
-- B y   F o x   H u
-- 2012-10-24T01:03:11Z
-- http://www.bloomberg.com/news/2012-10-24/fosun-pharma-raises-512-million-in-offering-at-bottom-of-range.html
Shanghai Fosun Pharmaceutical Group
Co. (2196) , a Chinese maker and distributor of drugs, raised $512
million in a share sale in Hong Kong after selling shares at the
low end of a marketed range.  Fosun Pharma (600196) , listed in Shanghai, sold about 336.1 million
shares at HK$11.80 apiece, according to a term sheet obtained by
 Bloomberg News . The shares were originally offered at as much as
HK$13.68 each, according to a  prospectus .  The final price is at about an 8.5 percent discount to
Fosun Pharma’s close of 10.39  yuan  in Shanghai yesterday. The
Hong Kong sale price would value the company at 12 times its
estimated 2013 earnings, according to people with knowledge of
the matter.  Shanghai Pharmaceuticals Holding Co., the second-biggest
drug distributor in China, trades at  14.5 times  the average
estimate for next year’s profit among analysts surveyed by
Bloomberg.  China International Capital Corp., Deutsche Bank AG,
JPMorgan Chase & Co. and UBS AG managed the sale, terms show.  To contact the reporter on this story:
Fox Hu in  Hong Kong  at 
 fhu7@bloomberg.net   To contact the editor responsible for this story:
Philip Lagerkranser at 
 lagerkranser@bloomberg.net  